Icaritin Sensitizes Hepatocellular Carcinoma to PD-L1 Therapy by NQO1-Dependent Ferroptosis Induction - PubMed
12 hours ago
- #immunotherapy
- #HCC
- #ferroptosis
- Icaritin sensitizes hepatocellular carcinoma (HCC) to PD-L1 therapy by inducing NQO1-dependent ferroptosis.
- The study explores icaritin's role in ferroptosis induction via the NQO1 pathway, impacting ROS, GPX4, and FTH1 markers.
- Icaritin enhances NK cell infiltration and reduces cancer-associated fibroblasts (CAFs), remodeling the tumor microenvironment (TME).
- Combination therapy of icaritin with anti-PD-L1 shows enhanced tumor suppression without increased toxicity.
- Findings support icaritin's dual action on ferroptosis and NK cell activation for HCC immunotherapy.